(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 13.75% to kr9.18 on Wednesday while Oslo Børs Benchmark Index_GI fell 0.71% to kr1,423.64.
ULTIMOVACS’s last close was kr8.07, 95.48% below its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.2.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.94%.
Moving Average
ULTIMOVACS’s value is way below its 50-day moving average of kr33.11 and way under its 200-day moving average of kr88.30.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was 4.86%, 1.00%, and 5.65%.
ULTIMOVACS’s highest amplitude of average volatility was 5.05% (last week), 4.27% (last month), and 5.65% (last quarter).
Yearly Top and Bottom Value
ULTIMOVACS’s stock is valued at kr9.18 at 22:31 EST, way under its 52-week high of kr178.60 and way above its 52-week low of kr6.07.
More news about ULTIMOVACS (ULTI.OL).
